These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6692356)

  • 81. [Toxicologic characteristics of anti-tumor medication lisomustine].
    Sidorin GI; Bitti MA; Lukovinkova LV; D'iakova LI; Skhodkina NI; Cherkashchenko OS
    Med Tr Prom Ekol; 2010; (4):19-24. PubMed ID: 20560493
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Bone marrow toxicity of cyclophosphazenes is related to their structure and the treatment schedule.
    Mulder NH; de Vries EG; Timmer-Bosscha H; van de Grampel JC
    Eur J Cancer Clin Oncol; 1986 Feb; 22(2):195-8. PubMed ID: 3699081
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The clinical evaluation of analogues, IV. Nitrosoureas.
    Carter SK
    Recent Results Cancer Res; 1980; 70():119-23. PubMed ID: 7355243
    [No Abstract]   [Full Text] [Related]  

  • 84. Proceedings: Strain differences in the carcinogenic action of N-ethyl-N-nitrosourea (ENU) in mice.
    Searle CE; Jones EL
    Br J Cancer; 1974 Aug; 30(2):181. PubMed ID: 4419452
    [No Abstract]   [Full Text] [Related]  

  • 85. The inheritance of susceptibility and resistance to the teratogenic effect of 1-ethyl-1-nitrosourea in inbred strains of mice.
    Diwan BA; Meier H
    Teratology; 1974 Feb; 9(1):45-9. PubMed ID: 4812357
    [No Abstract]   [Full Text] [Related]  

  • 86. [Effects of azathioprine-feeding or bone marrow transplantation on leukemogenic activity of N-butyl-N-nitrosourea (BNU) in Donryu rats (I). Sequential observations of immunological and histological changes in the subacute state].
    Furuta K; Ogiu T; Matsuoka C; Maekawa A
    Eisei Shikenjo Hokoku; 1984; (102):62-6. PubMed ID: 6398095
    [No Abstract]   [Full Text] [Related]  

  • 87. Influence of geomagnetic activity on mustophoran hematotoxicity.
    Blank MA; Blank OA; Gershanovich ML
    Dokl Biol Sci; 2005; 404():338-40. PubMed ID: 16405109
    [No Abstract]   [Full Text] [Related]  

  • 88. Effective means of reducing toxicity without concomitant sacrifice of efficacy of carcinostatic therapy.
    LePage GA; Kaneko T
    Cancer Res; 1969 Dec; 29(12):2314-8. PubMed ID: 5387263
    [No Abstract]   [Full Text] [Related]  

  • 89. [Hematological disorders and mortality induced in the mouse by 1,6-bis-chloro-ethyl-amino-1,6-desoxy-D-mannitol dihydrochloride: effect of bone marrow transfusion].
    RUVIDIC R
    Rev Fr Etud Clin Biol; 1962 Mar; 7():296-7. PubMed ID: 14495528
    [No Abstract]   [Full Text] [Related]  

  • 90. In vivo acute hematotoxicity of N,N'-bis[N-(2-chloroethyl)-N-nitrosocarbamoyl]cystamine (CNCC), a new nitrosourea analog.
    Blazsek I; Mathé G; Maral R; Jasmin C
    Toxicol Appl Pharmacol; 1984 Jun; 74(2):250-7. PubMed ID: 6740675
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hematological toxicity of repeated injections of (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea.
    Rebischung JL; Gougeon MD; Mori KJ; Lemaigre G; Mathé G; Jasmin C
    Cancer Res; 1984 Feb; 44(2):503-6. PubMed ID: 6692356
    [TBL] [Abstract][Full Text] [Related]  

  • 92. In vivo study of acute hematotoxicity of three nitrosoureas, chlorozotocin (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea, and (chloro-2-ethyl)-1-ribopyranosyl-3-nitrosourea.
    Mori KJ; Jasmin C; Hayat M; MacDonald JS; Mathé G
    Cancer Res; 1980 Nov; 40(11):4282-6. PubMed ID: 6451285
    [No Abstract]   [Full Text] [Related]  

  • 93. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
    Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
    Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hematologic effects of a single dose of methylnitrosourea.
    Seidel HJ
    Exp Hematol; 1977 Jan; 5(1):19-26. PubMed ID: 832681
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Combined interleukin 1 beta/interleukin 2 treatment in mice: synergistic myelostimulatory activity and protection against cyclophosphamide-induced myelosuppression.
    Proietti E; Tritarelli E; Gabriele L; Testa U; Greco G; Pelosi E; Gabbianelli M; Belardelli F; Peschle C
    Cancer Res; 1993 Feb; 53(3):569-76. PubMed ID: 8425189
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.